| Name | Title | Contact Details |
|---|
We`re the only on-demand healthcare concierge for employers, health plans and health systems. Join our customers who experience industry-leading engagement levels, satisfaction scores unseen in health care, better health outcomes, and substantial medical cost savings of more than 10 percent. Our team of compassionate, trusted professionals, supported by breakthrough science and technologies guide consumers through the healthcare system in a deeply personalized manner. We`ve been recognized as one of the nation`s 25 most promising companies by Forbes magazine, the fastest-growing private healthcare company by Inc. 500, and a top workplace by multiple news publications.
American Standards Testing Bureau is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Regenstrief Institute, Inc., an international leader in electronic medical records and health care data integration, is a medical research and development organization focused on improving quality of care, efficiency of health care delivery, and enhancing patient outcomes.
KSQ Therapeutics has built an industry-leading genome-scale precision functional genomics platform, called CRISPRomics, to pinpoint therapeutic nodes that directly correlate genomic function to disease with unprecedented certainty and speed. The company is deploying CRISPRomics for novel drug development across broad therapeutic areas and is currently advancing a proprietary pipeline of tumor- and immune-focused drug candidates. KSQ was founded by thought leaders in the field of functional genomics and pioneers of CRISPR screening technologies, and the company is located in Cambridge, Massachusetts.
Acucela is a clinical-stage biotechnology company that specializes in discovering and developing novel therapeutics to treat and slow the progression of sight-threatening ophthalmic diseases impacting millions of individuals worldwide. Acucela currently has the following candidates in development with Otsuka Pharmaceutical: emixustat hydrochloride for GA associated with dry AMD based on Acucela’s proprietary visual cycle modulation; and OPA-6566 for ocular hypertension and glaucoma.